There are currently 129 active clinical trials seeking participants for Pancreatic Cancer research studies. The states with the highest number of trials for Pancreatic Cancer participants are California, New York, Illinois and Texas.
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples from Colorectal Cancer Patients
NCT00899626
Recruiting
RATIONALE: Studying samples of tissue, blood, urine, stool, and other biological fluids from patients with cancer and from healthy volunteers undergoing colonoscopy or endoscopy may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is looking at gastrointestinal biomarkers in tissue and biological fluid samples from patients and participants undergoing colonoscopy, endoscopy, or surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Veterans Affairs Medical Center - Nashville, Nashville, Tennessee +1 locations
Conditions: Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Precancerous Condition
Register for Updates
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
NCT04275557
Recruiting
The Florida Pancreas Collaborative wants to partner with individuals who are known to have, or are suspected to have a pancreatic lesion, tumor, cyst, mass, cancer, or pancreatitis and are undergoing diagnosis and treatment at a participating institution. The goals of this project are to build a large database of information obtained from blood, tissue, medical images, surveys and information from routine care to develop noninvasive diagnostic approaches that could be used as decision-making too... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Florida Research Institute (FRI), Lakewood Ranch, Florida +2 locations
Conditions: Pancreatic Cancer, Pancreatic Cyst
Register for Updates
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
NCT04421820
Recruiting
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University of California, Los Angeles, Santa Monica, California +13 locations
Conditions: Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
Register for Updates
Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer
NCT02393703
Recruiting
The purpose of this study is to isolate and analyze exosomes, which are tiny carriers of important proteins and nucleic acids that serve as messenger systems in the blood and tissue. Blood and tissue from patients with pancreatic cancer will be compared with blood and tissue from patients with noncancerous pancreatic disease. Including patients without cancer will allow the investigators to establish "normal" values, which currently do not exist. The investigators will then look to see whether e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Pancreatic Cancer, Benign Pancreatic Disease
Register for Updates
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
NCT06736717
Recruiting
Pancreatic cancer is a deadly disease and will be the second leading cause of cancer related death behind lung cancer by 2030. Over 62,000 people are diagnosed each year in the United States with about 90% succumbing to the disease within 5 years. In the metastatic setting, NALIRIFOX, FOLFIRINOX and nab-paclitaxel-gemcitabine are standard treatment options in patients with good performance status (Eastern Cooperative Oncology Group \[ECOG\] 0/1). All three combinations have shown a survival adva... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Conditions: Pancreatic Cancer
Register for Updates
Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations
NCT05687188
Recruiting
This study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Moffitt Cancer Center, Tampa, Florida +1 locations
Conditions: Pancreatic Cancer
Register for Updates
Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer
NCT06423963
Recruiting
The purpose of the study is to examine the feasibility and acceptability of an exercise and nutrition "prehabilitation" program for patients preparing for pancreatic cancer resection (removal).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pancreatic Cancer
Register for Updates
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
NCT04117087
Recruiting
Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as patients with metastatic colorectal cancer who have exposure to 2 or more lines of chemotherapy, to evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with poly-ICLC adjuvant in combination with nivolumab and ipilimumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Colorectal Cancer, Pancreatic Cancer
Register for Updates
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
NCT06378047
Recruiting
This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Register for Updates
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069
Recruiting
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +15 locations
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Register for Updates
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479
Recruiting
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Advent Health Orlando Hospital, Orlando, Florida +18 locations
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Register for Updates
Collecting Medical Information and Tissue Samples from Patients with Pancreatic Cancer or Other Pancreatic Disorders
NCT00830557
Recruiting
RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic disorders in the future. PURPOSE: This clinical trial is collecting medical information and tissue samples from patients with pancreatic cancer or other pancreatic disorders.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona +2 locations
Conditions: Islet Cell Tumor, Pancreatic Cancer, Pancreatic Disease, Acute Pancreatitis, Chronic Pancreatitis, Hereditary Pancreatitis, Pancreatic Neuroendocrine Carcinoma
Register for Updates